Metagenomic and culturomic analysis of gut microbiota dysbiosis during Clostridium difficile infection.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
05 09 2019
Historique:
received: 05 04 2019
accepted: 20 08 2019
entrez: 7 9 2019
pubmed: 7 9 2019
medline: 4 8 2020
Statut: epublish

Résumé

Recently, cocktail of bacteria were proposed in order to treat Clostridium difficile infection (CDI), but these bacteriotherapies were selected more by chance than experimentation. We propose to comprehensively explore the gut microbiota of patients with CDI compared to healthy donors in order to propose a consortium of bacteria for treating C. difficile. We compared stool samples composition from 11 CDI patients and 8 healthy donors using two techniques: metagenomics, 16S V3-V4 region amplification and sequencing and culturomics, high throughout culture using six culture conditions and MALDI-TOF identification. By culturomics, we detected 170 different species in the CDI group and 275 in the control group. Bacteroidetes were significantly underrepresented in the CDI group (p = 0.007). By metagenomics, 452 different operational taxonomic units assigned to the species level were detected in the CDI group compared to 522 in the control group. By these two techniques, we selected 37 bacteria only found in control group in more than 75% of the samples and/or with high relative abundance, 10 of which have already been tested in published bacteriotherapies against CDI, and 3 of which (Bifidobacterium adolescentis, Bifidobacterium longum and Bacteroides ovatus) have been detected by these two techniques. This controlled number of bacteria could be administrated orally in a non-invasive way in order to treat CDI.

Identifiants

pubmed: 31488869
doi: 10.1038/s41598-019-49189-8
pii: 10.1038/s41598-019-49189-8
pmc: PMC6728329
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

12807

Références

Debast, S. B., Bauer, M. P. & Kuijper, E. J. European Society of Clinical Microbiology and Infectious Diseases: Update of the Treatment Guidance Document for Clostridium difficile Infection. Clin. Microbiol. Infect. 20, 1–26 (2014).
pubmed: 24118601 doi: 10.1111/1469-0691.12418
Lessa, F. C. et al. Burden of Clostridium difficile Infection in the United States. N. Engl. J. Med. 372, 825–834 (2015).
pubmed: 25714160 doi: 10.1056/NEJMoa1408913
Vincent, C. et al. Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium difficile infection. Microbiome 1, 18 (2013).
pubmed: 24450844 pmcid: 3971611 doi: 10.1186/2049-2618-1-18
Seekatz, A. M., Rao, K., Santhosh, K. & Young, V. B. Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection. Genome Med. 8, 47 (2016).
pubmed: 27121861 pmcid: 4847246 doi: 10.1186/s13073-016-0298-8
van Nood, E. et al. Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile. N. Engl. J. Med. 368, 407–415 (2013).
pubmed: 23323867 doi: 10.1056/NEJMoa1205037
Cammarota, G. et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66, 569–580 (2017).
pubmed: 28087657 doi: 10.1136/gutjnl-2016-313017
Hocquart, M. et al. Early Faecal Microbiota Transplantation Improves Survival in Severe Clostridium difficile Infections. Clin. Infect. Dis. (2017).
Martin, J. & Wilcox, M. New and emerging therapies for Clostridium difficile infection. Curr. Opin. Infect. Dis. 29, 546–554 (2016).
pubmed: 27753689 doi: 10.1097/QCO.0000000000000320
Schwartz, M., Gluck, M. & Koon, S. Norovirus Gastroenteritis After Fecal Microbiota Transplantation for Treatment of Clostridium difficile Infection Despite Asymptomatic Donors and Lack of Sick Contacts. Am. J. Gastroenterol. 108, 1367–1367 (2013).
pubmed: 23912408 doi: 10.1038/ajg.2013.164
Staley, C. et al. Successful Resolution of Recurrent Clostridium difficile Infection using Freeze-Dried, Encapsulated Fecal Microbiota; Pragmatic Cohort Study. Am. J. Gastroenterol (2017).
Baxter, M. & Colville, A. Adverse events in faecal microbiota transplant: a review of the literature. J. Hosp. Infect. 92, 117–127 (2016).
pubmed: 26803556 doi: 10.1016/j.jhin.2015.10.024
Viljoen, K. S., Dakshinamurthy, A., Goldberg, P. & Blackburn, J. M. Quantitative Profiling of Colorectal Cancer-Associated Bacteria Reveals Associations between Fusobacterium spp., Enterotoxigenic Bacteroides fragilis (ETBF) and Clinicopathological Features of Colorectal Cancer. PLoS One 10, e0119462 (2015).
pubmed: 25751261 pmcid: 4353626 doi: 10.1371/journal.pone.0119462
Armougom, F., Henry, M., Vialettes, B., Raccah, D. & Raoult, D. Monitoring Bacterial Community of Human Gut Microbiota Reveals an Increase in Lactobacillus in Obese Patients and Methanogens in Anorexic Patients. PLoS One 4, e7125 (2009).
pubmed: 19774074 pmcid: 2742902 doi: 10.1371/journal.pone.0007125
Alang, N. & Kelly, C. R. Weight Gain After Fecal Microbiota Transplantation. Open Forum Infect. Dis. 2, ofv004–ofv004 (2015).
pubmed: 26034755 pmcid: 4438885 doi: 10.1093/ofid/ofv004
Petrof, E. O. et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome 1, 3 (2013).
pubmed: 24467987 pmcid: 3869191 doi: 10.1186/2049-2618-1-3
Tvede, M., Tinggaard, M. & Helms, M. Rectal bacteriotherapy for recurrent Clostridium difficile-associated diarrhoea: results from a case series of 55 patients in Denmark 2000–2012. Clin. Microbiol. Infect. 21, 48–53 (2015).
pubmed: 25636927 doi: 10.1016/j.cmi.2014.07.003
Khanna, S. et al. A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection. J. Infect. Dis. 214, 173–81 (2016).
pubmed: 26908752 doi: 10.1093/infdis/jiv766
Lagier, J.-C., Cadoret, F. & Raoult, D. Critical Microbiological View of SER-109. J. Infect. Dis. 215, 161–162 (2017).
pubmed: 28077591 doi: 10.1093/infdis/jiw489
Turnbaugh, P. J. et al. The human microbiome project. Nature 449, 804–10 (2007).
pubmed: 17943116 pmcid: 3709439 doi: 10.1038/nature06244
Dhakan, D. B. et al. The unique composition of Indian gut microbiome, gene catalogue, and associated fecal metabolome deciphered using multi-omics approaches. Gigascience 8 (2019).
Eckburg, P. B. et al. Diversity of the Human Intestinal Microbial Flora. Science (80-.). 308, 1635–1638 (2005).
pmcid: 1395357 doi: 10.1126/science.1110591
Lagier, J. et al. The Rebirth of Culture in Microbiology through the Example of Culturomics To Study Human Gut Microbiota. Clin. Microbiol. Rev. 28, 237–264 (2015).
pubmed: 25567229 pmcid: 4284300 doi: 10.1128/CMR.00014-14
Lagier, J.-C. et al. Culture of previously uncultured members of the human gut microbiota by culturomics. Nat. Microbiol. 1, 16203 (2016).
pubmed: 27819657 doi: 10.1038/nmicrobiol.2016.203
Cassir, N. et al. Clostridium butyricum Strains and Dysbiosis Linked to Necrotizing Enterocolitis in Preterm Neonates. Clin. Infect. Dis. 61, 1107–1115 (2015).
pubmed: 26084844 doi: 10.1093/cid/civ468
Zhang, L. et al. Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization. Anaerobe 34, 1–7 (2015).
pubmed: 25817005 doi: 10.1016/j.anaerobe.2015.03.008
Lagier, J. et al. Microbial culturomics: paradigm shift in the human gut microbiome study. Clin. Microbiol. Infect. 18, 1185–1193 (2012).
pubmed: 23033984 doi: 10.1111/1469-0691.12023
Abt, M. C., McKenney, P. T. & Pamer, E. G. Clostridium difficile colitis: pathogenesis and host defence. Nat. Rev. Microbiol. 14, 609–620 (2016).
pubmed: 27573580 pmcid: 5109054 doi: 10.1038/nrmicro.2016.108
Angelakis, E. et al. Glycans affect DNA extraction and induce substantial differences in gut metagenomic studies. Sci. Rep. 6, 26276 (2016).
pubmed: 27188959 pmcid: 4870698 doi: 10.1038/srep26276
Lagier, J.-C., Dubourg, G., Amrane, S. & Raoult, D. Koch Postulate: Why Should we Grow Bacteria? Arch. Med. Res. 48, 774–779 (2017).
pubmed: 29523365 doi: 10.1016/j.arcmed.2018.02.003
Antharam, V. C. et al. Intestinal Dysbiosis and Depletion of Butyrogenic Bacteria in Clostridium difficile Infection and Nosocomial Diarrhea. J. Clin. Microbiol. 51, 2884–2892 (2013).
pubmed: 23804381 pmcid: 3754663 doi: 10.1128/JCM.00845-13
Lee, Y. J. et al. Protective Factors in the Intestinal Microbiome Against Clostridium difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. J. Infect. Dis. 215, 1117–1123 (2017).
pubmed: 28498996 pmcid: 5426375 doi: 10.1093/infdis/jix011
Schubert, A. M. et al. Microbiome Data Distinguish Patients with Clostridium difficile Infection and Non-C. difficile-Associated Diarrhea from Healthy Controls. MBio 5, e01021-14-e01021-14 (2014).
doi: 10.1128/mBio.01021-14
Milani, C. et al. Gut microbiota composition and Clostridium difficile infection in hospitalized elderly individuals: a metagenomic study. Sci. Rep. 6, 25945 (2016).
pubmed: 27166072 pmcid: 4863157 doi: 10.1038/srep25945
Hidalgo-Cantabrana, C. et al. Bifidobacteria and Their Health-Promoting Effects. Microbiol. Spectr. 5 (2017).
McFarland, L. V. Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. Antibiot. (Basel, Switzerland) 4, 160–78 (2015).
Hill, C. et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11, 506–514 (2014).
pubmed: 24912386 doi: 10.1038/nrgastro.2014.66
Milani, C. et al. Bifidobacteria exhibit social behavior through carbohydrate resource sharing in the gut. Sci. Rep. 5, 15782 (2015).
pubmed: 26506949 pmcid: 4623478 doi: 10.1038/srep15782
Wilson, B. C., Vatanen, T., Cutfield, W. S. & O’Sullivan, J. M. The Super-Donor Phenomenon in Fecal Microbiota Transplantation. Front. Cell. Infect. Microbiol. 9, 2 (2019).
pubmed: 30719428 pmcid: 6348388 doi: 10.3389/fcimb.2019.00002
Ott, S. J. et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. Gastroenterology 152, 799–811.e7 (2017).
pubmed: 27866880 doi: 10.1053/j.gastro.2016.11.010
Cassir, N. et al. Emergence of Clostridium difficile tcdC variant 078 in Marseille, France. Eur. J. Clin. Microbiol. Infect. Dis. (2017).
Seng, P. et al. Ongoing Revolution in Bacteriology: Routine Identification of Bacteria by Matrix‐Assisted Laser Desorption Ionization Time‐of‐Flight Mass Spectrometry. Clin. Infect. Dis. 49, 543–551 (2009).
pubmed: 19583519 doi: 10.1086/600885
Dubourg, G. et al. Culturomics and pyrosequencing evidence of the reduction in gut microbiota diversity in patients with broad-spectrum antibiotics. Int. J. Antimicrob. Agents 44, 117–24 (2014).
pubmed: 25063078 doi: 10.1016/j.ijantimicag.2014.04.020
Kim, M., Oh, H.-S., Park, S.-C. & Chun, J. Towards a taxonomic coherence between average nucleotide identity and 16S rRNA gene sequence similarity for species demarcation of prokaryotes. Int. J. Syst. Evol. Microbiol. 64, 346–51 (2014).
pubmed: 24505072 doi: 10.1099/ijs.0.059774-0
Browne, H. P. et al. Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation. Nature 533, 543–546 (2016).
pubmed: 27144353 pmcid: 4890681 doi: 10.1038/nature17645
Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. J. Mol. Biol. 215, 403–10 (1990).
pubmed: 2231712 doi: 10.1016/S0022-2836(05)80360-2
Quast, C. et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 41, D590–6 (2013).
pubmed: 23193283 doi: 10.1093/nar/gks1219
Million, M. et al. Increased Gut Redox and Depletion of Anaerobic and Methanogenic Prokaryotes in Severe Acute Malnutrition. Sci. Rep. 6, 26051 (2016).
pubmed: 27183876 pmcid: 4869025 doi: 10.1038/srep26051
Angelakis, E. et al. Gut microbiome and dietary patterns in different Saudi populations and monkeys. Sci. Rep. 6, 32191 (2016).
pubmed: 27578328 pmcid: 5006041 doi: 10.1038/srep32191
Dhariwal, A. et al. MicrobiomeAnalyst: a web-based tool for comprehensive statistical, visual and meta-analysis of microbiome data. Nucleic Acids Res. 45, W180–W188 (2017).
pubmed: 28449106 pmcid: 5570177 doi: 10.1093/nar/gkx295
Huttenhower, C. et al. Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012).
doi: 10.1038/nature11234
Segata, N. et al. Metagenomic biomarker discovery and explanation. Genome Biol. 12, R60 (2011).
pubmed: 21702898 pmcid: 3218848 doi: 10.1186/gb-2011-12-6-r60

Auteurs

Sophie Amrane (S)

Aix Marseille Univ, IRD, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Marie Hocquart (M)

Aix Marseille Univ, IRD, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Pamela Afouda (P)

Aix Marseille Univ, IRD, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Edmond Kuete (E)

Aix Marseille Univ, IRD, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Thi-Phuong-Thao Pham (TP)

Aix Marseille Univ, IRD, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Niokhor Dione (N)

Aix Marseille Univ, IRD, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Issa Isaac Ngom (II)

Aix Marseille Univ, IRD, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Camille Valles (C)

Aix Marseille Univ, IRD, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Dipankar Bachar (D)

Aix Marseille Univ, IRD, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Didier Raoult (D)

Aix Marseille Univ, IRD, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Jean Christophe Lagier (JC)

Aix Marseille Univ, IRD, MEPHI, IHU-Méditerranée Infection, Marseille, France. jclagier@yahoo.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH